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ABSTRACT 
The most sensitive target for lead toxicity is the central nervous system. 
Cognitive and behavioral defects can already take place at very low 
exposure levels, especially in children. Aluminium exposure has been 
connected with the manifestation of neurodegenerative changes after 
long-term exposures in adults. Despite of numerous studies on these 
metals, the mechanisms of their neurotoxicity have not been solved yet. 
The present study was set up to investigate the neurotoxic potentials 
of aluminium and lead by using isolated rodent brain synaptosomes, 
human neuroblastoma cell line and rat primary neural cell culture. The 
evaluations of synaptosomal membrane effects were made both in vitro 
and in vivo. 
Lead decreased clearly activity of the synaptosomal integral protein 
ATPase, but there was no marked decrease on the AChE activity in vitro. 
In in vivo experiments, lead in the diet caused a slight but not statistically 
significant decrease in ATPase and AChE activities in rat brain 
synaptosomes. 
 The 90-day aluminium (Al-lactate 91.8 mg/kg/day) oral exposure of 
rats dereased both ATPase and AChE activities, measured two weeks 
after the last dosing. Immediately after the 90-day exposure, significant 
decrease in the AChE activity was only found in rats coexposed to 
aluminium and ethanol (EtOH) (3.0 g/kg/day). Coexposure with EtOH had 
no effect on the blood aluminium content, but aluminium decreased the 
whole blood EtOH content significantly. In in vitro tests, the coexposure of 
aluminium with EtOH ATPase and AChE increased the EC50 values. 
Total ATPase and AChE activities decreased concentration-dependently 
in vitro. 
In isolated cerebral synaptosomal membranes of knockout GDNF+/- 
and wild type (WT) mice, aluminium and lead exposures caused a dose-
dependent decrease in the ATPase activity.  
The acute cell toxicity of lead was much greater than that of 
aluminium. Generally, the cell-toxic reactions were found at higher 
concentrations than the changes in the brain synaptosomal integral 
enzymes, which seem to be markers of the neurotoxic insults of 
aluminium and lead. 
Key words: aluminium, lead, ethanol, neurotoxicity, synaptosomes, ATP, 
ATPase, AChE, cell toxicity, SH-SY5Y cell line, GDNF 
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INTRODUCTION 
Environmental and occupational exposure to aluminium and lead have 
caused  health problems by interaction with biological systems. No 
normal physiological functions have been discovered for aluminium and 
lead. These metals are known to be neurotoxicants, both in experimental 
animals and in humans. Exposures to aluminium and lead are common 
all over the world, but the most serious problems are found in the 
developing countries.  
The neurotoxic potencies of lead and aluminium are different. Lead 
has caused neurotoxic effects at considerably low exposure levels 
especially in children (Banks et al. 1997). Aluminium exposure has been 
connected with the manifestation of neurodegenerative changes after 
long-term exposures in adults (Yokel 2000, Zatta et al. 2003). 
Aluminium is the most abundant metal in the earth's crust 
(approximately 8 %). Man cannot avoid being exposed to it from various 
sources, such as food, drinking water and pharmaceutical products. 
Adults will get an average of 2-10 mg/day with food (Alfrey 1983, 
Pennington and Schoen 1995). The exposure depends on how much 
aluminium contaminates the water supply, how much aluminium is used 
in local water treatment, and how much aluminium is leached from the 
soil by the acid rain. Aluminium exposure may also be a consequence of 
the long-term use of some medicines, antacids and vaccines, and of 
dialytic treatments of patients. In humans with chronic renal failure, 
dialysis treatment has caused encephalopathy, osteomalacia, and 
anemia, due to aluminium accumulation (Flaten et al. 1996). Many 
different mechanisms have also been connected with aluminium 
neurotoxicity. Aluminium accumulation in the brain can lead to 
neurofibrillary degeneration (Good and Perl 1993), damage of the 
cholinergic system (Zubenko and Hanin 1989, Gulya et al. 1990), 
impairment in brain energy balance (Walker et al. 1989, Cho and Kim 
1991, Octive et al. 1991), and disturbances in second messenger 
systems (Yamamoto et al. 1990, Publicover 1991, Franceschetti et al. 
1992). There may be a link between aluminium exposure and 
Alzheimer´s disease (AD) or other neurodegenerative diseases, but the 
ethiology and the role of aluminium in these diseases are poorly 
understood. It has been shown that senile plaques in the brain tissue, the 
pathological hallmarks of AD, contain amorphous aluminosilicates (Candy 
et al. 1986, Clauberg and Joshi 1992). Epidemiological studies on the 
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effects of aluminium in drinking water have shown positive relations 
between aluminium exposure and Alzheimer´s disease (Flaten 2001). 
Accumulation of aluminium in the brain may, in combination with other 
neurotoxic factors, e.g. alcohol, increase the risk of neurotoxic effects 
(Davis 1993). Aluminium in the brain may be one of the cofactors in the 
alcoholic dementia.  
Compared to aluminium, the neurotoxic mechanisms of lead are 
better known. Lead ranks second of the 275 substances on the 
ATSDR/EPA Priority List of Hazardous Substances for 2003 (ATSDR 
Information Center 2003). Aluminium is number 194 on the same list. 
Lead is a more powerful neurotoxicant than aluminium, and even very 
low concentrations in blood can cause deleterious neurological effects 
(Goyer 1993). Lead is found in food, water, air, dust and soil. 
Occupational exposure to lead may occur in the manufacture of metal 
products and battery components etc. Lead is used in the synthesis of 
fuel additives and in the preparation of paints and pigments. The main 
target for lead toxicity is the central nervous system (CNS). The major 
neurologic manifestations of lead  poisoning are neuronal disorders, lead 
encephalopathy, hearing deficits, peripheral neuropathy and cognitive 
deficits (Goyer and Clarkson 2001). Long-term occupational exposure 
(>20 yr) to lead has been suggested as a risk factor in the development 
of Parkinson´s disease (PD) (Kuhn et al. 1998). 
It has been suggested that the mechanisms of the neurotoxic effects 
of lead may be due to its interference with neurotransmitter systems, 
cellular calcium (Ca) homeostasis, and enzyme activities (Guilarte 1997, 
Finkelstein et al. 1998, Savolainen et al. 1998, Bressler et al. 1999, 
Loikkanen et al. 2003). Interactions of lead with calcium metabolism and 
the activation of protein kinase C  have been considered as  potential 
mechanisms  of the cellular toxicity of lead (Loikkanen et al. 1998). 
Both aluminium and lead can enter the CNS (Zheng et al. 2003). Both 
metals can also penetrate the neural cell membrane. The first action site 
for lead and aluminium is the neural cell membrane and its sensitive 
functions, including the regulatory activities of the membrane-bound 
integral enzymes acetylcholinesterase (AChE) and adenosine 
triphosphatase  (ATPase). 
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REVIEW OF THE LITERATURE 
1. Environmental prevalence of aluminium and lead 
Many metals are known to be essential to man, but no biological 
functions have been discovered for heavy metals such as lead (Pb) or for 
the third-group metal aluminium (Al). These non-physiological metals are 
known to be neurotoxic and they can affect multiple organ systems in 
man and animals. Lead is widely distributed in our environment since 
prehistoric times, and its sources are many. It is found in food, water, air 
dust and soil. Occupational exposure to lead occurs in mining and in the 
refining and smelting of lead. It has been used in the synthesis of fuel 
additives and in the preparation of paints and pigments (Bondy 1988). 
The neurotoxicity of lead has been of great concern, because it is 
ubiquitous in the environment, but the exact mechanisms of its toxicity 
have not been solved yet (Loikkanen et al. 1998, Raunio and Tähti 2001). 
Aluminium is the third most abundant metal in the earth's crust, with 
an average concentration of about 8 %. Man cannot avoid being exposed 
to it from various sources. It does not occur naturally in the element form 
since it is a chemically reactive metal. In agriculture, aluminium affects 
perhaps as much as 40% of arable soils. Aluminium toxicity in agriculture 
has been discussed for the first time in 1918 (Hartwell and Pember 
1918). In fresh waters acidified by acid rain, aluminium toxicity has led to 
fish extinction. In Flaten´s review (2001) nine out of 13 published studies 
of the correlation between aluminium in drinking water and  Alzheimer´s 
disease (AD) showed statistically significant positive relations. The 
studies were conducted in Norway, Ontario USA, England, France, 
Switzerland and Canada (Flaten 2001). Previously several studies have 
clearly established aluminium as a potential neurotoxicant to humans and 
experimental animals (Yokel et al. 1994). 
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2. Human exposure to aluminium and lead 
2.1. Exposure to aluminium 
Major sources of aluminium for human exposure are acidic leaching into 
groundwater, residues in foods, cooking utensils, food packaging, 
cosmetics, and some pharmaceutical products. Aluminium is also present 
as dust in the air (Ganrot 1986). Foods with high aluminium content 
include tea, herbs, grain products, processed cheeses and salt, but there 
is no report of dietary toxicity of aluminium to healthy individuals. Average 
adult dietary aluminium intake is about 5-10 mg/day (Pennington and 
Schoen 1995). The amount of diet aluminium is small compared to the 
amount of aluminium in pharmaceutical products, such as in antacids, 
dialysis fluid and some vaccines (Bergfors et al. 2003). Drinking water 
provides about 1% of the normal daily aluminium intake (Yokel 2000).  
Exposure of humans to aluminium in drinking water has been 
supposed to be the major environmental factor for the development of AD 
(Yokel 2000). In neutral water the concentrations of dissolved aluminium 
are usually less than 0.1 mg/l. In some parts of the world, acid 
precipitation has increased the concentration of aluminium (Flaten 1991). 
Aluminium is also widely used in water treatment as a coagulant, to 
reduce the number of small particles and improve the colour of water. If 
the treatment process is functioning optimally, aluminium values are 
lower in treated water than in groundwater (Flaten 2001). 
Cosmetic products can contain magnesium (Mg2+) and aluminium 
silicates. These silicates had no adverse effects on human skin in daily 
use for a one-week exposure period. However, Mg-Al silicate was found 
to be a weak skin irritant in some studies with rabbits (Doll 1993). 
The first human deleterious condition generally accepted to be 
causally related to aluminium exposure was dialysis encephalopathy in 
patients with chronic renal failure (Flaten 2001). Children and young 
adults with renal disease are at the greatest risk for aluminium toxicity, 
due to their rapidly growing skeleton and immature brain functions (Alfrey 
1993, Advenier et al. 2003). 
2.2. Exposure to lead 
Lead is the most ubiquitous toxic metal and is detectable in practically all 
phases of the environment. Lead is found in food, water, air, dust and 
soil. Pollution of the environment occurs though the smelting and refining 
of lead, the burning of petroleum fuels, smelting of other metals and the 
burning of coal and oil. Metallic lead deriving from shotgun cartridges or 
used as fishing weights is realeased into the environment and remains 
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available to organisms. The uptake and accumulation of lead by aquatic 
organisms from water and sediments are influenced by environmental 
factors such as temperature, salinity, pH and humic and alginic acid 
content. In fish, lead is mostly accumulated in gill, liver, kidney and bone 
tissues.. 
In a review by Grandjean (1993), lead concentrations in 
paleopathologic studies have been determined in well-preserved human 
bones or teeth. Pre-pollution samples generally show lead concentrations 
of about 1% of the current levels in industrialized countries (Grandjean 
1993). Increased blood lead concentrations are related to smoking, 
drinking alcoholic beverages, eating vegetables, living in urban 
residences, and exposure caused by lead-using industries. The use of 
lead as antiknocking agent in fuels has caused environmental exposure. 
However, recently lead has been replaced with other agents in most 
countries. 
Occupational exposures to lead occur in the manufacture of metal 
products, (Cullen et al. 1983, Flora 2002), in the synthesis of fuel 
additives and in the preparation of paints and pigments. Exposure to lead 
is also a principal hazard in stained glass work, jewelry making, ceramic 
painting and lead paint removal.  
3. Toxicities of aluminium and lead 
3.1. Aluminium 
Aluminium is very poorly absorbed from the gastrointestitinal tract. Its 
absorption from the gastrointestinal channel is estimated to be 1-2% 
(Gitelman et al. 1995). In combination with organic acids, e.g. lactic acid, 
the absorbtion is better than in the free form. Gastric acidity, fluoride 
ingestion, parathyroid hormone and vitamin D can theoretically modulate 
aluminium absorption. However, in renal failure the absorbed aluminum is 
retained and can markedly alter the body aluminium burden with resulting 
toxicity (Alfrey 1985). Ingestion of antacids based on aluminium salts for 
treating gastritis or ulcers has caused an increasing risk for exposure to 
aluminium in chronic heavy drinkers (Davis 1993). Alcohol may cause 
increased permeability of the intestinal mucosa to the entry of aluminium. 
The amount of aluminium (<1%) that is systemically absorbed is excreted 
principally in the urine and in the feces. 
Aluminium absorption may depend heavily on idiosyncratic factors 
such as age and possible renal or gastrointestinal disease. It has long 
been known that fluoride (F) increases the levels of aluminium in plasma 
as much as citrate, whereas aluminium decreases the absorption of 
fluoride from the gastrointestinal tract (Ahn et al. 1995, Berthon 2002, 
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Fattoretti et al. 2003). Aluminium may also decrease the absorption of Ca 
and iron (Fe), which are essential metals of the body. The binding of 
phosphorus in the gastrointestinal tract can lead to osteomalacia 
(Loghman-Adham 1999, Berthon 2002, Malluche 2002). 
The effects of silicon (silicic acid) on aluminium absorption and 
excretion have been described in many experiments (Yokel et al. 1996, 
Exley et al. 1996, Birchall et al. 1996, Parry et al. 1998). Silicon reduces 
the gastrointestinal absorption and increases the renal excretion of 
aluminium. It increases the filterable fraction of aluminium in the blood by 
forming hydroxyaluminosilicates, which are not absorbed across 
gastrointestinal membranes nor across the kidney tubular membrane 
(Birchall et al. 1996, Bellia et al. 1996, Parry et al. 1998). Phosphate 
excretion can be enhanced by aluminium, which forms insoluble 
aluminium phosphates in the gastrointestinal tract. When great amounts 
of aluminium are consumed as an antacid, aluminium accumulation and 
toxicity can be the result (Yokel 2000). 
Aluminium bioavailability depends directly on the oxidation states of 
Al3+ in vivo. Al3+ binds strongly to oxygen-donor ligands such as citrate 
and phosphate. The aqueous (coordination) chemistry of aluminium is 
complicated due to the tendency of many aluminium complexes to 
hydrolyze and form polynuclear species, many of which are sparingly 
soluble. Thus there is considerable variation among the aluminium 
stability constants reported for several important ligands. The complexity 
of the aqueous chemistry of aluminium has also affected aluminium 
toxicity studies. Serum fractionation studies show that most of aluminium 
is protein-bound, primarily to the serum iron transport protein transferrin 
(Tf). Albumin appears to play little, if any, role in serum transport. (Harris 
et al. 1996, Berthon 2002). Aluminium circulates in the plasma 
predominantly as the trivalent ion (Al3+) like iron (Fe3+). Since the binding 
of Al3+ oxidation state to Tf is weaker than that of Fe3+, it is also likely to 
circulate in the plasma as a conjugate with other small-molecular-weight 
compounds, such as citrate (Allen et al. 1995, Ackley and Yokel 1997). In 
plasma, 80-90% of aluminium binds to Tf, for which there are receptors in 
many body tissues. Also bone tissue may be a sink for aluminium 
(DeVoto and Yokel 1994). The interaction of aluminium with fluoride and 
magnesium may exacerbate aluminium accumulation in the bone tissue 
(Ng et al. 2004). 
Aluminium is considered to cross the blood brain-barrier (BBB) mainly 
by binding to Tf, using the same transport system as Fe3+ (Martin 1986, 
Roskams and Connor 1990, Fatemi et al. 1991, McGregor et al. 1991, 
Radunovic et al. 1998).  Tf-mediated transport of aluminium into the CNS 
is relatively slow, but studies by Allen et al. (1995) have presented an 
efficient, energy-dependent aluminium carrier that removes the metal 
efficiently from brain extracellular fluid into brain cells or blood (Allen et al. 
1995). Small-molecular-weight complexes of aluminium citrate may be 
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important in carrying aluminium across the BBB. This transporter is 
predominantly located at the BBB, rather than at neuronal or glial cell 
membranes (Ackley and Yokel 1997). Aluminium accumalation in the 
brain increases with age and is higher in the grey matter than in the white 
matter (Ganrot 1986, Candy et al. 1992). The cholinergic system, which 
is important in learning and memory, has been suggested as a possible 
target for aluminium neurotoxicity. There is evidence suggesting that 
ageing causes free radical-induced lipid peroxidation, damage of neural 
membranes, and increase in the permeability of the BBB (Favarato et al. 
1992, Oteiza et al. 1993). 
 
 
Figure 1.  Chronological continuum of neurotoxic events following aluminium 
exposure in the mammalian nervous system.  
Aluminium accumulation can lead to irreversible changes in the brain 
cells, but short-term effects may be reversible due to the repair and 
plasticity phenomena in the CNS (Figure 1). The mechanisms causing 
these changes are e.g. neurofibrillary degeneration (Good and Perl 1993, 
Shin et al. 1995, Huang et al. 1997, El Rahman 2003), and damage of 
the cholinergic system (Zubenko and Hanin 1989, Gulya et al. 1990). 
Aluminium is an etiopathogenic factor in diseases related to long-term 
dialysis treatment and has been shown to cause dialysis encephalopathy 
in renal patients (Alfrey 1984). Aluminium has been controversially 
invoked as an aggravating factor or cofactor in AD (Shore and Wyatt 
1983, van der Voet et al. 1991, Jansson 2001, Flaten 2001) and PD 
(Yasui et al. 1992, Altschuler 1999, Uversky et al. 2002) as well as in 
other neurodegenerative diseases (Campbell et al. 2001, Uversky et al. 
2002, Zatta et al. 2003). Some studies have proved that senile plaques, 
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one of the pathological hallmarks of AD, contain amorphous 
aluminosilicates (Candy et al. 1992, Clauberg and Joshi 1992, Campbell 
2002). However, the role of aluminium in AD and dementia is still 
speculative. A detailed mechanistic basis for the hypothesis that 
aluminium may exacerbate events associated with AD in certain 
conditions is clearly emerging (Campbell 2002, Berthon 2002). The 
ageing CNS is particularly susceptible to aluminium toxic effects, which 
may increase the cell load of oxidative stress and may contribute, as an 
aggravating factor, to the development of neurodegenerative events, as 
observed in AD (Fattoretti et al. 2003). 
Aluminium toxicity acts in two ways depending on the level of 
contamination. Low aluminium levels from environmental sources have 
been associated with different types of dementias. The acute toxicity of 
aluminium compounds is low, the reported oral LD50 values being in the 
range of several hundreds to 1000 mg aluminium / kg body weight per 
day. LD50 values for inhalation have not been identified. In the short-term 
animal studies in the diet or drinking-water (Flaten 2001) only minimal 
effects have been observed at the highest doses administered (70 to 300 
mg aluminium / kg body weight per day). In parenteral administration of 
aluminium, systemic effects (e.g. kidney dysfunction) have been found at 
dose levels 70-300 mg / kg  per day (Anonymous 1997).  
Interactions between aluminium and other chemicals are supposed to 
modify the biological effects of aluminium in the body. Epidemiological 
studies in the USA have reported lower incidence of primary 
degenerative dementia (mostly AD) in a county with a high concentration 
of fluoride in drinking water, relative to the counties with less fluoride in 
the drinking water (Still 1994). Epidemiological studies in the Western 
Pacific and West New Guinea have suggested that low Ca2+, Mg2+, and 
high aluminium and manganese (Mn) in river, soil and drinking water may 
be implicated in the pathogenetic process of foci of amyotrophic lateral 
sclerosis (ALS) and  PD (Oteiza et al. 1993). In studies in Norway it was 
found that the mortality of dementia patients was higher with high 
concentrations of aluminium in drinking water (Flaten and Bolviken 1991). 
Studies which confirm similar associations have also been published in 
Great Britain (Martyn et al. 1989) and in some other countries (Doll 1993, 
McLachlan et al. 1996). 
3.2. Lead 
In adults, 5 to 15 % of ingested lead is absorbed in the gastrointestinal 
tract (Lidsky and Schneider 2003). Lead is eliminated unabsorbed in 
feces and urine. Other excretion routes are hair, nails and sweat (<8%) 
(Rabinowitz et al. 1976). An assessment of the total body burden of lead 
revealed higher level, (164-8 mg) in adult male subjects than in females 
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(103-6 mg). Over 90% of the total body burden of lead in adults is in 
bone, of which over 70% is found in the dense bone. In male adults 
occupationally exposed to lead, 97% was in bone  (Barry 1975). The total 
body burden of lead may be devided into at least two kinetic pools, which 
have different rates of turnover. The larger and slower pool is in the 
skeleton, with a half-life of more than 20 years. The other pool is the 
more lable soft tissue pool. Lead is also known to cross the placenta, and 
cord blood lead levels generally correlate with maternal blood lead levels, 
but are slightly lower (Clark 1977, Chuang et al. 2001). In children, lead is 
more readily absorbed from gastrointestinal canal than in adults and 
there is also evidence that certain genetic and environmental factors can 
increase the detrimental effects of lead on neural development, thereby 
rendering certain children more vulnerable to lead neurotoxicity (Bellinger 
et al. 1987, Needleman 1994, Markowitz 2000, Lidsky and Schneider 
2003, Needleman and Landrigan 2004). 
Blood lead levels as low as 10 µg/100ml have been associated with 
impaired neurobehavioral development in children, and blood levels over 
30 µg/100ml have been associated with neurotoxic effects, elevated 
blood pressure, and other adverse effects in adults. The dietary exposure 
of lead that results in the above blood levels has been estimated to be 
60-150 µg/day for children, 250 µg/day for pregnant women and 750 
µg/day for adults (Chuang et al. 2001). The safe levels are even lower 
when the possibility of individual variations is taken into account. Mean 
blood lead level for the whole USA population aged 1 year and older is 
2.3 µg/100 ml, 2.2% of the population having levels >10 µg/100 ml (Pirkle 
et al. 1998). Considerably high blood lead concentrations (15 µg/100 ml) 
have been measured in populations in Belgium, Germany, India, Italy, 
Malta, Mexico, Poland, United Kingdom and the USA (Baron and 
Schweinsberg 1989). In contrast, very low blood lead concentrations 1.6 
µg/100 ml, have been found in populations far from industrial areas, such 
as at the Faroe Islands (Grandjean et al. 1992). In many countries, 
especially in developing countries, childhood lead poisoning is a common 
national public health risk. In Lebanon the mean lead blood levels of 6.6 
µg/100 ml have been measured, and 14% of the children have >10 µg/ 
100 ml. The analysis showed that elevated blood lead of children was 
associated with paternal manual jobs and the residence being located in 
high-traffic areas, with using hot water for cooking, exposure to coal and 
living in older buildings (Markowitz 2000, Nuwayhid et al. 2003). In 
Helsinki, the mean concentration of lead in the blood of children in a 
centrally situated day-care centre was 4,6 µg/100 ml in 1983, 3,0 µg/100 
ml in 1988 and 2,6 µg/100 ml in 1996 (Pönkä 1998). Average blood lead 
concentrations have decreased in the USA (Annest et al. 1983) and in 
Europe (Ducoffre et al. 1990). The main reason is the reduction of lead in 
gasoline. 
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The hematological system is one of the important targets of lead 
toxicity. Lead has been shown to induce changes in the composition of 
red blood cell membrane proteins and lipids (Fukumoto et al. 1983, 
Horiguchi et al. 1991) and to inhibit hemoglobin synthesis (Gurer-Orhan 
et al. 2004). More than 90% of the lead in blood is in red blood cells and 
transported by blood to various organs and tissues (Chisolm, Jr. 1974, 
Grandjean and Andersen 1982). There are two major compartments for 
lead in blood cells, one associated with the membrane and the other with 
hemoglobin. Small fractions may be related to other red blood cell 
components. Plasma and serum may contain diffusible fractions of lead 
in equilibrium with soft tissue. This fraction is difficult to measure, but 
there is an equilibrium between red cell and plasma lead.  
Lead in the CNS tends to be concentrated in gray matter and certain 
nuclei, and there may be differences among brain regions in their 
sensitivity to lead (Widzowski and Cory-Slechta 1994). Exposure to lead 
has been associated with many neuropsychological and behavioral 
disturbances, including ataxia, short-term memory impairment, inability to 
concentrate, impotence, headache and disorientation (Cullen et al. 1983). 
The symptoms of acute lead encephalopathy usually appear over several 
days and are associated with high blood levels of lead < 40-50 µg/100ml 
(Bressler and Goldstein 1991). Epidemiological studies have also shown 
a strong relationship between the level of lead in blood and bone, and the 
success of performance in Intelligence Quotient (IQ) tests and in other 
psychometric tests (Bressler et al. 1999).  
Since learning requires a remodeling of synapses in the brain, lead 
may specifically affect synaptic transmission. Although the molecular 
targets for lead are unknown, the evidence over many years has shown 
that lead disrupts processes regulated by Ca2+ (Bressler and Goldstein 
1991, Raunio and Tähti 2001). It has been assumed that lead activates 
protein kinase C in intact cells, and that learning deficits caused by lead 
are due to events regulated by protein kinase C, most likely to occur at 
the synapse close to the postsynaptic membrane of the neuron (Bressler 
et al. 1999). Because lead can mimic Ca2+  in the CNS, it  can enter cells 
via Ca2+  channels and activate protein kinase C, a process normally 
caused by Ca2+. 
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4. Experimental studies on the neurotoxicity of 
aluminium 
4.1. Animal models 
The first studies demonstrating aluminium neurotoxicity in experimental 
animals were conducted by Siem and Döllken more than 100 years ago 
(Yokel and Golub 1997). 
The CNS of rabbits is particulary prone to the same neurofibrillary 
changes induced by aluminium and its salts as that of humans 
(Wisniewski et al. 1980). Neurofibrillary changes have also been noted in 
cats, ferrets and dogs. It has been shown that the neurotoxin Al-maltolate 
induces apoptosis in the rabbit brain (Savory et al. 2003), and this in vivo 
model has been used to study the neuroprotective properties in the CNS 
toxicity caused by aluminium (Ghribi et al. 2002).  
Rodents are the most frequently used whole animal models in the 
research of aluminium exposure. In mice, percutaneous uptake 
significantly increases aluminium in urine, serum and whole brain, 
especially in the hippocampus, compared to control mice. This 
accumulation of aluminium in the brain is greater than that caused by 
dietary exposure (Anane et al. 1995). In rats, the effects of chronic 
aluminium exposure on Ca2+ levels increase significantly with the 
increase in aluminium doses (Sanchez et al. 1997). It has been shown 
that considerable amounts of aluminium injected into pregnant and 
suckling rats were transferred to the brain of the fetuses and sucklings 
(Yumoto et al. 2001). This is supposed to induce neurobehavioral 
dysfunctions in the offspring. There are also  reports which demonstrate 
rapid transport of aluminium across the BBB in rats (Peng et al. 1992). 
Neurotoxic actions of aluminium in the rat brain affect both glial reactions 
and cholinergic projections. Low doses of aluminium (5.4 µg during 5 
days) cause pathological changes of cholinergic fibres in the rat brain, 
which is in agreement with the observation that aluminium causes 
cognitive defects in this species (Platt et al. 2001). 
4.2. In vitro models 
There is evidence of aluminium cell toxicity in different studies, even 
though it is not considered highly cytotoxic (Dominguez et al. 1995, 
Campbell et al. 2001, Guo and Liang 2001, Sargazi et al. 2001, Toimela 
et al. 2004). Aluminium uptake and toxicity have been mostly studied in 
neuronal and astroglial cells (Zielke et al. 1993, Suarez-Fernandez et al. 
1999, Levesque et al. 2000, Kawahara et al. 2001) and in human and 
mouse neuroblastoma cell lines (Shi and Haug 1990, Atterwill et al. 1992, 
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Abreo et al. 1999). Astrocytes and neurons have been used to investigate 
the effects of long-time exposures to aluminium. There are indications 
that astrocytes are especially sensitive to aluminium. Exposure to 
aluminium for 8-12 days caused changes in the morphology of 
astrocytes. Exposure for over 15-18 days reduced astrocyte viability by 
50% and degenerated DNA fragmentation (Suarez-Fernandez et al. 
1999) Astrocytic membrane-bound Na+, K+ -ATPase has been shown to 
be more sensitive to aluminium than synaptosomal Na+, K+ -ATPase 
(Rao 1992). In murine neuroblastoma cells, aluminium has been shown 
to change Fe3+ uptake and inhibit cell growth (Abreo et al. 1999). In 
cultured neurons the degeneration and accumulation happened after 
more than 3-week exposure to aluminium, but not after 1-week exposure 
(Kawahara et al. 2001). On the contrary, aluminium-induced 
excitotoxicity, based on the glutamate-mediated mechanism, may be 
more relevant in neurons than in astrocytes. Aluminium may induce an 
astrocytic factor that makes neurons more susceptible to glutamate-
mediated toxicity, or it may inhibit this factor and thus reduce the 
excitotoxic effects on neurons (Sass et al. 1993).  
Disturbances in the regulation of apoptosis in neurons or astrocytes 
may contribute to the mechanism of neurodegenerative diseases, such 
as AD (Stefanis et al. 1997). Apoptosis and aluminium-induced 
cytotoxicity have been recently studied in cultured astrocytes and 
neurons. The results indicated that aluminium can induce cell death, 
apoptosis, and decrease significantly the viability of cultured cortical 
neurons in a dose-dependent manner (Ohyashiki et al. 2002, Johnson 
and Sharma 2003, Fu et al. 2003). In acute experiments (24 hours), 
aluminium has been found to cause abnormal clustering of neural cells in 
culture, and neuronal death (Toimela et al. 2004). Longer exposures of 
neural cultures have shown apoptotic condensation and fragmentation of 
chromatin in aluminium-treated astrocytes, but not in cocultured neurons 
(Suarez-Fernandez et al. 1999). 
In cell cultures from chick forebrain, the brain stem and the optic 
tectum were treated with aluminium for 7 days, the effects of aluminium 
on the cell viability and differentiation were found to be brain area-
specific. The highest sensitivity was observed in the optic tectum (Muller 
and Bruinink 1994). 
In studies of the permeability of biological membranes, the in vitro 
models have been shown to be the most relevant ones. Aluminium 
accumulates intracellularly, and this mechanism is dependent on many 
factors, the most important of which are cell type, physical-chemistry of 
extracellular medium and presence of carrier proteins (Exley and Birchall 
1992). The ability of aluminium to modify membrane-bound Na+, K+ -
ATPase activity has been observed by several investigators (Caspers et 
al. 1990, Rao 1992, Caspers et al. 1993, Lal et al. 1993, Caspers et al. 
1994, Zatta et al. 1994, Zatta et al. 1995, Sarin et al. 1997, Silva and 
  
 
 
24 
Goncalves 2003). In all these studies, aluminium treatment was found to 
disturb various membrane-bound enzymes, e.g. in terms of activity 
changes. ATPase and AChE are membrane bound integral proteins in 
the neural membrane. Aluminium may interfere with various biochemical 
processes including acetylcholine metabolism, and can thus act as a 
possible etiopathogenic cofactor. In experimental studies with mice, 
aluminium has caused increase in the AChE activity both in vivo and in 
vitro (Zatta et al. 2002). 
There are reports suggesting that aluminium may participate in the 
neurotoxic action of amyloid beta-peptide, the principal component of 
senile plaques characteristic of AD (Bondy et al. 1998, Exley and 
Korchazhkina 2001, Silva and Goncalves 2003). At low concentrations, 
aluminium may have effects on the amyloid beta-peptide action and 
further on the Na+, K+ -ATPase activity in cultured rat hippocampal 
neurons. This may be the reason of the loss of Ca homeostasis and cell 
degeneration, which are common features of AD and aluminium 
intoxication (Mark et al. 1997, Bores et al. 1998).  
5. Experimental studies on the neurotoxicity of lead 
5.1. Animal models 
The neurotoxicity of lead has been experimental studied mostly in 
rodents. Compared to humans, the absorption of lead in rodents is much 
lower. About 10% of ingested lead is absorbed by humans, while the 
corresponding figure for rats is only 1%. The same blood lead levels that 
cause neurological defects in humans do not result in clear behavioral 
disturbances in rats (Rostron 1982a, Rostron 1982b, Petit et al. 1992). 
Chronic lead exposure during brain development is known to affect 
functions of the CNS in rats. Rats at different developmental stages, 
chronically exposed to 200 mg/ lead in drinking water, reflect a higher 
vulnerability to lead-induced functional deficits in the immature rats than 
in adults (Bull et al. 1983). The hippocampal changes are greater in 
immature rats than in mature ones (Altmann et al. 1993). The rat studies 
showed that gastrointestinal absorption of lead in young animals was 
greater than that in adult animals (Aykin-Burns et al. 2003).   
Several in vivo studies have reported that moderate levels of lead 
exposure alter the morphology of neurons in a variety of experimental 
animals. The first studies reporting effects of lead on neuronal 
morphology showed that prenatal exposure (69 µg /100ml blood lead at 
birth) in rats results in perturbation of the normal cortical synaptic 
production (Crofton et al. 1980, McCauley et al. 1982). Alfano and Petit 
reported increasing dendritic branching close to the cell body and 
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decreasing total number of branches in the hippocampal granule cells of 
rats exposed postnatally to lead (Alfano and Petit 1982). Increased 
dendritic branching has been found in cortical pyramidal neurons of 
guinea pigs exposed to low lead levels (10-30 µg /100ml in blood) 
(Legare et al. 1993). Most studies have shown morphological alterations 
in dendrites from several brain regions, which supports the idea that lead 
is a developmental teratogen (Cookman et al. 1987, Breen and Regan 
1988, Regan 1993). 
5.2. In vitro models 
In vitro models offer opportunities for examining the specific targets and 
mechanisms by which lead alters neuronal morphology. These models  
are especially valuable when the chronology and the mechanisms of 
lead-induced alterations are studied. 
There are many studies on the different mechanisms for lead 
neurotoxicity: interaction between Ca and lead in cellular processes 
(Simons 1993), alterations in neurotransmitter release (Bressler et al. 
1999), activation of protein kinase C (Laterra et al. 1992, Long et al. 
1994, Loikkanen et al. 1998), and inhibition of glutamate uptake into 
astrocytes (Loikkanen et al. 2003), inhibition of glutamine synthetase 
activity (Engle and Volpe 1990, Sierra and Tiffany-Castiglioni 1991). 
There are numerous studies on the cell toxic mechanisms of lead with 
different neuron and glial cell cultures or membrane preparations. Lead 
can enter nerve cells and has been observed experimentally to be most 
concentrated within the mitochondria (Silbergeld and Adler 1978). Lead 
has an effect on neurotransmitter functions and can interact with ions. 
Ca2+ ions play a special role in the CNS in the release of 
neurotransmitters from presynaptic nerve endings, and lead may disturb 
this release (Raunio and Tähti 2001, Marchetti 2003). 
The BBB and access to the CNS are known to be one of the main 
targets for lead toxicity  (Zheng et al. 2003). Lead is known to accumulate 
in the choroid plexus to a great extent, and this accumulation increases 
with age (Manton et al. 1984). Animal studies also support these findings 
(Zheng et al. 1991). The BBB protects the CNS against environmental 
chemicals by different complementary mechanisms. Toxic metal 
molecules can penetrate the BBB, which can lead to chemical-induced 
neurotoxicities (Zheng 2001). Only recently, good in vitro BBB models 
have been developed for the evaluation of the passage of xenobiotics 
into the brain (Toimela et al. 2004). 
Astrocytes provide signals to endothelial cells for the maintenance of 
BBB integrity, and the damage of astrocytes by lead may disturb the 
integrity of BBB (Bressler and Goldstein 1991, Raunio and Tähti 2001). 
The passage of lead across BBB is regulated by different mechanisms. It 
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has been assumed that the transport mechanism is passive diffusion of 
Pb2+. However, there may be an active mechanism from brain endothelial 
cells back to blood by Ca2+ -ATPase (Deane and Bradbury 1990, Simons 
1993, Zheng et al. 2003). When considering the CNS toxicity of lead, 
both the effects on the BBB and on the neural tissue should be taken into 
account. 
Lead interaction with Ca2+ ions is based on the so called ¨mimicry¨ 
phenomenon. Lead can take the place of Ca2+ in import regulatory 
mechanisms. Picomolar concentrations of lead can replace micromolar 
concentrations of Ca2+ in protein kinase C enzyme. Lead activates 
protein kinase C in intact cells and induces the expression of new genes 
by a mechanism dependent on protein kinase C (Naarala et al. 1995, 
Bressler et al. 1999, Marchetti 2003). The neurotoxicity of lead might be 
due to events regulated by protein kinase C, most likely to occur at the 
synaptic site (Bressler et al. 1999, Toimela et al. 2004). 
 Addition of lead into in vitro study models can cause effects which are 
more prominent than those produced by a comparable amount of lead in 
the tissue studied after in vivo exposure. Cremin and Smith suggest that 
in vitro models might not reflect accurately the effects of chronic low-level 
in vivo lead exposure, even though the reason for this is not clear yet 
(Cremin, Jr. and Smith 2002). 
6. GDNF animal model in neurotoxicology 
Neurotrophic factors regulate many critical phases in the ontogeny of 
neurons, e.g. the number of neurons in a given population, neurite 
branching, and synaptogenesis. 
Recently, a genetically regulated glial-cell-line-derived neurotrophic 
factor (GDNF) has raised interest in evaluations of the neuroprotection in 
animal models. GDNF is a polypeptide, distantly related to some 
transforming growth factors. It has been shown that the GDNF factor is a 
neuronal survival factor for mature and developing rodent brain (Trupp et 
al. 1995). It was originally identified as a survival factor for midbrain 
dopaminergic neurons. The GDNF factor family and related ligands 
maintain several neuronal populations in the CNS. In animal models of 
PD, GDNF protects dopamine neurons and rescues motor neurons in 
vivo, which makes it a valuable candidate for therapeutic use in several 
neurodegenerative diseases (Sariola and Saarma 2003). Direct injection 
of aluminium into rabbit brain results in a number of neuropathological 
and biochemical changes similar to those in AD (Huang et al. 1997), and 
GDNF has been reported to have a marked anti-apoptotic effect in rabbit 
brain during aluminium exposure (Ghribi et al. 2001). 
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The GDNF factor has been shown to reduce biochemical and 
behavioral changes induced by exposure to drugs. It also seems to play a 
role in the neurotoxic effects of drug abuse, and it is important in the 
regulation of the dopaminergic systems (Airavaara et al. 2004).  
7. Cell membranes as a target of neurotoxic effects 
The basic structure of all biological membranes is a fluid-like phospholipid 
bilayer, into which freely diffusing integral globular proteins are 
embedded to varying degrees (Singer 1990, Singer 2004)(Figure 2). All 
cell membranes have certain common features: their major components 
are proteins and lipids. However, the detailed chemical structure of 
membranes can vary considerably from one cell type to another. The 
major lipids are phospholipids such as phosphatidylcholine and 
phosphatidylethanolamine. In the cell membrane, the hydrophilic ends of 
these phospholipids are exposed to the aqueous exterior of the cell and 
the cytoplasm, while the hydrophobic ends are located in the interior of 
the membrane.  
 
1.
2.
3.
4.
5.
The cytoplasmic side of cell membrane
 
Figure 2. Schematic representation of the cell membrane structure. 1. Integral 
protein (e.g. AChE) 2. Carbohydrate part of glycolipid 3. Lipid bilayer 4. Integral 
protein (e.g. ATPase) 5. Peripheral protein 
Proteins comprise 20 – 80 % of biomembranes (Figure 2). Proteins 
are biochemically active components of the membrane, and both diversity 
and different receptors of enzymes are characteristic of each particular 
membrane. The membrane proteins are now generally viewed as being 
folded so as to present nonpolar hydrophobic inner surfaces, which can 
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interact with the lipid bilayer. The polar regions of a protein can interact 
with the lipid head groups at the surface of membrane proteins. Many 
membrane proteins are transmembranous and extend through the lipid 
bilayer. Other membrane proteins are probably bound to the membrane 
exclusively through interactions with other proteins.There are two kinds of 
membrane proteins, peripheral and integral ones, according to the 
degree of harshness of the treatment required to release the protein from 
the cell membrane. The peripheral proteins are thought to be weakly 
bound to the membrane surface by electrostatic interactions either with 
the lipid head groups or with other proteins (Gennis 1989). 
Membrane proteins do not all diffuse freely in the fluid lipid bilayer, 
and there is evidence of differentiated lateral domains within the 
membrane (Jacobson et al. 1987). The membrane allows some 
substances to pass through it while excluding others, and its permeability 
can be regulated. Electron microscopy and X-ray diffraction analysis have 
been very important in defining cell membrane morphology. These 
methods have been used to confirm the bilayer model, but they are very 
limited in revealing the molecular details of the membrane. 
Due to many active transport and receptor mechanisms, the neural 
membranes have been found to be vulnerable to many different 
neurotoxic substances. The synaptosomal membrane integral proteins 
acetylcholinesterase AChE and ATPase have been considered as 
sensitive markers of the neurotoxicity insults of organic solvents 
(Vaalavirta and Tähti 1995, Tähti et al. 1997) and pyrethroid insecticides 
(Kakko et al. 2003).  
8. Integral proteins ATPase and AChE 
The arrival of a nerve impulse at the nerve endings leads to a series of 
events involving the entry of natrium and the exit of potassium. 
Restoration of the ionic equilibria of Na+ and K+ through the membrane is 
carried out by the Na+/K+ pump. The Na+/K+ pump is the most important 
ion pump in neurons, and its function is controlled by the ATPase (Na+, 
K+ -ATPase)(Figure 2). This enzyme has a critical role in restoring the 
membrane gradients of Na+ and K+ after neuronal excitation. The Na+ 
maintained by the pump is used as a source of energy for driving other 
transport mechanisms such as Na+/Ca2+ exhange and the uptake of 
organic compounds, e.g. amino acids. Na+, K+ -ATPase is also important 
for retaining membrane potential and for the regulation of cell volume 
(Horisberger et al. 1991, Lees 1991). Na+, K+ -ATPase is a particle-bound 
enzyme enriched in the nerve ending or synaptosomal membranes. The 
activity of Na+, K+ -ATPase is essential for the maintenance of numerous 
reactions in the isolated synaptosomes. This lends interest to the 
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knowledge of the possible regulatory mechanisms of Na+, K+ -ATPase 
activity in the synaptic region. There is evidence that brain Na+, K+ -
ATPase activity may be modified by certain neurotransmitters and by 
insulin (Rodriguez de Lores 1992). 
Both AChE and ATPase belong to the small integral proteins of the 
membrane and are thus closely related to the lipid structure of the 
membrane (Figure 2). The ATPase of the cell membrane is mainly 
located on the cytoplasmic side of the membrane, but it also has some 
extensions through the membrane (Marchesi et al. 1976). AChE is 
located in the membrane mainly on the outer half of the phospholipid 
bilayer, and it is known to exist in variations of quaternary structures 
(Lees 1991). Integral proteins are very important e.g in controlling the 
movement of ions across the membrane, and thus vulnerable to toxic 
effects of chemicals (Tähti et al. 1999). In the brain, 40% of the energy 
released is used by the ATPase in order to maintain ionic gradients 
across cell membranes even in resting conditions (Lees 1991). All 
ATPases are dependent on a phospholipid bilayer for their activity and 
transport function. For optimal activity, a certain degree of membrane 
fluidity is required, which is maintained by the presence of unsaturated 
fatty acids in the phospholipids of the membrane (Schuurmans and 
Bonting 1981). 
Isoenzyme forms of Na+, K+ -ATPase exist as complexes of alpha  
and beta subunits. Three different alpha units and three different beta 
units have been deduced by DNA sequence analysis (Urayama et al. 
1989). The phosphorylation site and the ATP-binding site are located on 
the alpha subunit on the cytoplasmic site of the Na+, K+ -ATPase, 
whereas the ouabain binding site is on the extracellular site. The cardiac 
glycoside ouabain is a Na+, K+ -ATPase inhibitor, and it may play a role in 
apoptotic cell death (Yu 2003, Hartford et al. 2004). The inhibition of Na+, 
K+ -ATPase by ouabain blocks the various functions in isolated 
synaptosomes: synthesis of low molecule weight substances as well as 
Na+  and K+ entry (Rodriquez de Lorez Arnaiz 1992). Isoenzymes 
containing high-affinity ouabain sites (alpha2 and alpha3)  are the most 
prevalent in brain neurons. The isoenzyme alpha3 may be specific to 
neurons, while the isoenzyme alpha1 with lower affinity for ouabain is 
present in glial cells and in neurons (Sweadner 1989, Markwell et al. 
1991). Several other ATPase activities have been identified, which are 
associated with ion pumps. These include the Ca2+, Mg2+ -ATPase and 
K+, H+ -ATPase. Their transport functions differ from each other, but they 
probably have the same structures. 
Ionic imbalances have been strongly implied in cell death, both in the 
nervous system and in other tissues. The role played by ion pumps in 
transporting potentially toxic substances through the cell membrane is 
only beginning to be understood in describing the cytotoxic mechanisms 
of neuronal damage. The involvement of Na+, K+ -ATPase inhibition in the 
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neuronal death depends on the degree and the length of time for which 
the enzyme is inhibited. Na+, K+ -ATPase is found in large amounts in 
synaptic nerve endings, where neurotransmission takes place. It is 
especially abundant in nerve ending membranes. Thus, the isolated 
synaptosomes of the brains of experimental animals have been used in 
studies of ATPase functions and in the evaluations of neurotoxic insults. 
9. Ethical considerations 
Toxicity testing in animals is the means for assessing the potential 
hazards of chemical exposure in humans. The use of animals in safety 
testing and in scientific experiments has raised many ethical questions. 
The fact is that there has been an increase in the number of animals in 
Finland (other than fish) used in experiments, 4 % / year from 2000 to 
2002 (Ministry of Agriculture and Forestry in Finland 2003), mainly 
because of the increasing use of modified gene techniques in 
experiments. The tendency is the same in all Western countries. 
There are national and international rules for regulating animal 
experiments. European Union Directive 86/609/EEC regulates the use of 
animals for scientific purposes in the EU. The Directive seeks to improve 
the control on the use of laboratory animals and to set minimum 
standards for housing and care, as well as for the training of the 
personnel handling animals and supervising the experiments. It also aims 
to reduce the numbers of animals used, by encouraging the development 
and the validation of alternative methods (Louhimies 2002). There is a 
need to develop and validate acceptable alternative methods to whole 
animal tests in toxicology. The principles according to which alternative 
tests should be validated have been agreed upon at an international 
level, although the actual process by which the validation process is 
conducted varies between different validation authorities (Worth and Balls 
2002). 
Scientific communities have to promote humane behavior towards 
laboratory animals and to reduce the sum total of pain and fear inflicted 
on animals by man. The three ethical principles replacement, reduction 
and refinement (3R´s principle) have become the leading rules in 
laboratory animal science and welfare since 1959 (Russell and Burch 
1959). According to 3R´s principle, a frequently asked question should be 
whether animal studies are irreplaceable or whether some other models 
could be used instead (Rusche 2003). In vitro systems compared to in 
vivo systems have some advantages: they are often technically cheaper 
and easier, their arrangement is simplified, and interfering factors are 
minimized. On the other hand, in vivo studies allow more comprehensive 
understanding of whole systems in the body. This is true especially in the 
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studies of toxicology, which are highly complex processes and involve 
multiple different steps. There are differences between humans and the 
animal species used in experiments. However, the basic cellular 
mechanisms are strikingly similar, and thus animal studies, together with 
in vitro studies, are at least indicative of human toxic effects and  
diseases. 
 
 
 
¨Where a will is there´s a way, 
Every rat can have his day, 
New discoveries every week 
Serve to promote humane technique. ¨ 
 
Prof. William M.S. Russell 
3rd World Congress on Alternatives and Animal Use in Life Sciences 
Bologna 1999 
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AIMS OF THE STUDY 
The purpose of this study was to compare, in vivo and in vitro, the 
neurotoxic effects of aluminium and lead on the rodent cerebrum at the 
cellular level, and to evaluate the synaptosomal membrane integral 
proteins as targets for aluminium and lead. 
 
The specific aims of the present study were 
 
1. to study the effects of aluminium and lead on rat brain 
synaptosomal membrane integral proteins ATPase and AChE in 
vitro, 
2. to study the effects of 90-day oral exposure of rats to aluminium 
and EtOH on the synaptosomal integral proteins and to evaluate 
the combined effects of aluminium and EtOH in vitro, 
3. to study the role of the neurotrophic factor (GDNF) in the effects of 
aluminium and lead on the integral proteins in synaptosomes 
isolated from knockout GDNF+/- and WT mice, and 
4. to evaluate the cell-toxic effects of aluminium and lead in the 
human neuroblastoma cell line (SH-SY5Y) with studies on the 
cellular ATP content. 
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MATERIALS AND METHODS 
1. Experimental animals (I-IV) 
In comparative neurotoxicity studies in vivo ( II, III), outbred WI:Han (II)  
and HsdBrlHan:WIST (III) were used. The rats were supplied by Harlan, 
Indianapolis, USA and Harlan, Netherlands. The animals were housed 
during the experiments in conventional and semi-barrier conditions, 
limited-access animal rooms in Laboratory Animal Center, University of 
Helsinki. 
In in vitro studies the synaptosomes were prepared from outbred male 
Wistar rats from the University of Tampere (I) and from male WI:Han rats 
from Harlan (II). On the effects of aluminium and lead on ATPase activity 
in vitro, the knockout GDNF+/- mouse cerebral synaptosomes were used 
(IV) (Sariola and Saarma 2003). The mice are bred in Viikki Laboratory 
Animal Center, University of Helsinki, in barrier conditions. The genotype 
of the mice was determined as described by Pichel et al. (Pichel et al. 
1996). 
All animals had the commercially available rodent diet Altromin 1314, 
Denmark (I, II, III) and Teklad 2018, England (IV) and drinking tap water 
ad libitum. Animal care and housing were performed according to 
European  and national legislation and recommendations (Nevalainen et 
al. 1996).  
All the experimental protocols were approved by the institutional 
animal care and use committees of the University of Helsinki and the 
University of Tampere. The animals were used only to prepare 
synaptosomes (I, II, IV) and to start the primary cultures (I). 
2. In vivo exposures (II,III) 
2.1 Exposure of rats to aluminium and ethanol   
In the in vivo study (III) two or three rats (HsdBrlHan:WIST) were placed 
together in plastic cages (Tecniplast MAK III), male and female rats in 
separate cages. In the beginning of the exposure the rats were eight 
weeks old. Male rats weighed approximately 390g and females 250g. 
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During the experiment, the weights of the animals were measured and 
recorded once a week. AlLc3 from Fluka (Buchs SG, Switzerland) with 
EtOH did not cause any significant difference in the body weights of the 
treated rats, compared to the control animals.  
The rats were randomly divided into four groups, each group 
consisting of ten animals (five males and five females). The experimental 
groups were: (1) control group, (2) AlLc3 (91.8 mg/kg body weight) group, 
(3) AlLc3 (91.8 mg/kg) with EtOH (3.0 g/kg) group, and (4) EtOH (3.0 
g/kg) group. The substances were given orally by cavage once a day. 
EtOH was given in a 30% (v/v) solution. The treatment lasted for 90 days. 
At the end of the exposure the animals of each group were randomly 
divided into two final examination groups of equal size: A) rats examined 
immediately after the 90-day exposure and B) rats examined two weeks 
after the exposure. 
2.2 Exposure of rats to lead  
WI:Han outbred rats were exposed to inorganic lead PbCO3 in the animal 
diet LACTAMIN R 469 (II). The concentration of lead in the test diet was 
29.0 mg/kg. In the control diet LACTAMIN R 468, the concentration of 
lead (PbCO3) was 0.58 mg/kg. The animals had the diets and purified tap 
water ad libitum. Three female rats were eating the test diet during the 
whole of the pregnancy and the suckling. After weaning, the litters (n=8)  
were fed with the test diet for two months. The control animals (n=18) of 
the same ages were similarly housed in MAK III cages, three rats in one 
cage, and obtained the control diet and drinking tap water ad libitum.  
3. Measurements of rat blood aluminium, lead and 
ethanol contents (II,III) 
After the 90-day exposure (III), blood samples  were taken by heart 
puncture from the rats anesthetized with carbon dioxide (CO2), before 
decapitation and brain preparation. CO2 was used because it has no 
effect on the fluidity of cell membranes, unlike many chemical 
anesthetics. The serum was separated and pipetted in special acid-
washed test tubes for aluminium samples. Aluminium was determined in 
the test laboratory of the Institute of Occupational Health, Helsinki. A 
procedure developed from the method of Wang et al. (Wang et al. 1991) 
was used. In this method, fourfold dilution is made of the serum in 0.07 % 
nitric acid. The analysis was performed in pyrolytically coated graphite 
tubes using a platform technique and electrothermal atomic absorption 
spectrometry. The instrument combination was Perkin-Elmer 
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Zeeman/5100 PC AA spectrometer equipped with a HGA 600 graphite 
furnace and an AS 60 autosampler. 
The whole blood lead levels (II) (B-Pb) were analyzed by atomic 
absorption spectrophotometry according to Olsen and Jatlow in the 
Regional Institute of Occupational Health, Tampere (Olsen and Jatlow 
1972). 
For the EtOH measurements (III); 100-200 µl blood samples were 
taken from the tip of the tails of 10 rats (5 rats randomly from the EtOH 
group and 5 rats from the EtOH / aluminium group). The samples were 
collected in the morning after the last day of the 90-day exposure. The 
EtOH determinations were made with head-space gas chromatography 
(Eriksson et al. 1977) in the National Public Health Institute, Department 
of Alcohol Research, Helsinki.  
4. Synaptosome preparations of rats and mice (I-IV) 
After decapitation and the preparation of the brains, the cerebral 
synaptosomes of the rodents (Figure 3) were isolated by using a non-
toxic isoosmotic Percoll gradient method described by Nagy and 
Delgado-Escueta (Nagy and Delgado-Escueta 1984). The cerebrum was 
gently separated from the cerebellum, brain stem and meninges and 
immediately placed in the isolation medium I containing 0.93 M sucrose 
(Merk, Darmstadt, Germany), 15mM N-2-hydroxyethyl-piperazine-N'-2-
ethaneethylene-diaminetetraacetic acid (HEPES, Sigma, St. Louis, USA), 
and 0.3 mM ethylenediaminetetraacetic acid (EDTA, Sigma, St. Louis, 
USA). The brain tissue was homogenized in ten times the volume of 
medium I at 800 revolutions/min (rpm) with a teflon glass homogenizer. 
All the procedures were carried out at the temperature of 0-4ºC. The 
crude homogenate was centrifuged at 3000 rpm for ten min to isolate a 
pellet containing nuclear and cell debris. The supernatant was further 
centrifuged at 10 000 rpm for 20 min to produce a crude mitochondrial 
pellet, which was resuspended in isolation medium I (3.0 ml per gram of 
original wet tissue). All the Percoll solutions were prepared just before 
use. The stock solution of isoosmotic Percoll (SIP) was made by adding 
nine parts of 2.5 M sucrose to the Percoll solution (Sigma, St. Louis, 
USA). Lower- density media were prepared by appropriate dilution of SIP 
with medium II, which contained 0.72 M sucrose, 15 mM HEPES(pH 7.2), 
and 0.3 mM EDTA. The pH of the gradient solutions was adjusted to pH 
7.5. Percoll step gradients were prepared by overlaying 4.0 ml 16% 
Percoll solution with 4.0 ml 10 % solution. The resuspended 
mitochondrial pellet was diluted with eight volumes of 8.5 % Percoll 
solution to adjust the final concentration of Percoll to 7.5 %. 4.5 ml of this 
suspension was layered onto the 10 %/16 % Percoll gradient. After 
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centrifugation at 12 000 x g for 20 min, the synaptosomes were collected 
and stored on ice in a refrigerator until use on the same day, or deep-
frozen for later determinations of the enzyme activities. 
 
Figure 3. Photograph of synaptosomes isolated from the rat cerebrum 
4.1 In vitro exposure of the synaptosomes  
Al-lactate (purum 98%, Fluka, Switzerland) exposure (IV) was studied in 
0.3 mM, 0.9 mM, 1.5 mM, 2.0 mM and 2.8 mM concentrations in the 
incubation medium [67 mM tris (hydroxymethyl) aminomethane hydro-
chloride acid buffer pH 7.6, Boehringer Mannheim]. 
The membrane fractions (IV) were exposed to different concentrations 
(0.001mM, 0.003mM, 0.006mM, 0.009mM, 0.015mM, and 0.030mM) of 
lead chloride (PbCl2). The exposure for one hour was carried out in glass-
stoppered test tubes at 37°C under continuous stirring.  
5. Rat brain neural cells culture and exposure (I) 
The primary neural cell culture was established from fetal rat brains (I). 
The whole brains of 17-19 days old rat fetuses (Sprague-Dawley, 
University of Tampere) were prepared and isolated from meninges under 
microscope in ice-cold sterile Dulbecco´s Phosphate Buffer Saline (PBS, 
Gibco, UK). The brains were cut into 1 mm pieces in a known volume of 
PBS, and dissociated by trypsinization by adding the same volume of 
0.25% trypsin (Gibco, Painsley, UK) in Minimum Essential Medium 
(MEM, Gibco, UK). After incubation (I), the enzyme dissociation was 
ended by adding twice the volume of plating medium (PM). The cell  
suspension was centrifuged, the supernatant was discarded, and the 
pellet was resuspended into PM. This procedure was followed by a gentle 
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trituration. After 5 min, the triturated cell suspension was transferred into 
another tube and centrifuged at 150 x g for 5 min, after which the 
supernatant was discarded. The cells were resuspended into PM. The 
cells were cultured (0.038 brains/cm2) in poly-L-lysine (Sigma, St. Louis, 
USA) –coated Falcon tissue culture flasks at 37oC in an incubator with 
5% of CO2 and in constant humidity. On the second day the medium was 
removed. To stop the mitotic activity of non-neuronal cells, 1:150 dilution 
of the fluorodeoxyuridine-uridine solution (FDUR, 0.2% 5-
fluorodeoxyuridine and 0.5% uridine, Sigma, St. Louis, USA) in the 
feeding medium was added. The feeding medium consisted of 5% horse 
serum, 6 g/l glucose, 0.1% gentamysin and 0.1% L-glutamine in MEM. 
On the fourth day the FDUR solution was removed and changed into 
feeding medium. Half of the feeding medium was changed every second 
day, and the cells were cultivated for seven days, after which the cells 
were collected and stored at -70oC. 
The neural cells membranes were exposed in the incubation medium 
to five different metal concentrations (3µM, 6µM, 9µM,15µM, 30µM) as 
aluminium chloride (AlCl3), AlLc3, PbCl2, and lead acetate [Pb(C2H3O2)2] . 
All chemicals were of p.a. grade. The exposures were conducted in test 
tubes at 37oC under continuous stirring for one hour, after which the 
enzyme activities were measured (I). 
 
6. Neuroblastoma cell line cultures (IV) 
Neuroblastoma SH-SY5Y cells (IV) were cultured in standard 
conditions (at 37oC with 5 % CO2 in a humidified incubator) according to 
the instructions of the originator, American Type Culture Collection, USA. 
Cell culture media and supplements were obtained from Gibco (UK). The 
cell line was grown in 1:1 minium essential medium (MEM)/Ham´s F-12 
Kaighn´s Modification Medium supplemented with 1% AB-AM, 10% foetal 
bovine serum (FBS), 2 mM L-glutamine and 0.1 mM non-essential amino 
acids. After reaching 80 % confluency, the cells were subcultured on 96-
well plates (40 000 cells/well) for cell toxicity determinations.  
7. Toxicity tests 
7.1 ATP measurements (IV) 
After a 24h exposure to the metals, the acute cell toxicity was evaluated 
by determining the total ATP content of SH-SY5Y cells. The 
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bioluminescence activity of the samples was measured after addition of a 
luciferase reagent. The enzyme luciferase catalyzes the formation of light 
from ATP and luciferin (Nagy and Delgado-Escueta 1984). To measure 
the total ATP content of the cells, 5 µl of ice-cold 10% TCA was added 
into the culture medium to stop the cellular reactions. After TCA 
treatment, the plates were shaken 600 rpm min and then put into a -75oC 
freezer overnight. The plates were thawed and freezed three times to 
release all ATP from the cells. After that, 25 µl of the cell suspension was 
moved on a black 96-well microplate (ThermoLabsystems Black 
Cliniplate No. 950 2867). Then the luciferase reagent (Thermo 
Labsystems) and Tris-acetate buffer were combined in the ratio 1:4. After 
addition of 100 µl of this combined mixture, the luminescence 
measurements were made with Luminoskan Ascent luminometer 
(ThermoLabsystems)  with the integration time 1000 ms.  
7.2 ATPase measurement (I-IV) 
The ATPase activities of the synaptosomes were assayed with a 
modification of the discontinuous method developed by Phillips and 
Hayes (Phillips and Hayes 1989). The method is based on the 
determination of liberated inorganic phosphate (Pi) from the substrate 
ATP (Lowry et al. 1951). The reaction mixture contained 67 mM of 
tris(hydroxymethyl)aminomethanehydrochloride acid buffer (pH 7.6) (Tris-
HCl, Boehringer Mannheim, Germany), 30 mM adenosine-5'-triphosphate 
(ATP, Sigma, St. Louis, USA), 100 mM magnesium chloride, 2 mM 
sodium chloride, 400 mM potassium chloride and 0.1 ml of synaptosomes 
in a fixed volume of 2.0 ml. The samples were incubated for one hour at 
37ºC in tightly stoppered test tubes under continuous stirring. The 
reaction was stopped by addition of 2.0 ml of ice-cold 10% trichloroacetic 
acid (Merck, Darmstadt, Germany). The supernatant was separated by 
centrifugation at 1900 rpm for 10 min. The Pi was determined from 1 ml 
samples of the supernatant. The absorbance measurements were made 
with Perkin Elmer Lambda 1 UV/VIS spectrophotometer at the 
wavelength 750 nm. The final values were calculated taking into account 
the protein content of the synaptosomal sample. The normalized values 
were calculated as percentages of the control level in each 
measurement. 
7.3 AChE measurement (II,III) 
In the determinations of AChE activity, the method described by Ellman 
et al. was used (Ellman et al. 1961). The method is based on the 
measurement of the rate of thiocholine production in the hydrolysis of the 
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substrate acetylcholine. Thiocholine, when reacting with 
dithiobisnitrobenzoic acid (DTNB), produces a yellow colour, which can 
be measured photometrically. In the reaction mixture, 0.4 ml of 
synaptosome fractions (average protein content 0.2-0.4 mg/ml) and 2.6 
ml 0.1 M phosphate buffer pH 8.0 (containing 0.749 g KH2PO4, 16.820 g 
Na2HPO4  2 H2O and 1000 ml water) was incubated for 30 min at 37ºC 
under continuous stirring. The samples were moved into photometer 
cells, and 100 µl 5.5-dithiobis-2-nitrobenzoic acid (DTNB, Mr 396.4 g/mol, 
Sigma, D-8130, St Louis, USA) was added. 20 µl substrate, 0.075 M 
acetylcholine iodide (Sigma, A-5751, St. Louis, USA) was added into the 
photometer cells. The absorbances were measured at 412 nm after one 
min and five min. The normalized values were calculated as percentages 
of the control level in each measurement. 
8. Protein determinations 
The protein contents (I-IV) of the synaptosomes were determined with the 
method of Lowry et al. (Lowry et al. 1951). Bovine serum albumin (Sigma, 
A-4378) was used for standards. 
9. Statistical calculations 
Five independent enzyme activitiy measurements of different membrane 
isolations were performed at each exposure level in triplicates. The 
enzyme activities were expressed as nmol Pi/h/mg protein, and the 
activity of the metal-treated samples was expressed as per cent of control 
activity. In statistical calculations, Student´s two-tailed t-test was used (I, 
II). 
Student's two-tailed t-test was used to compare the enzyme activities 
and aluminium - ethanol concentrations of the treated groups to the 
corresponding parameters in the control group. The in vitro response 
curves were obtained by fitting the data by a non-linear regression 
analysis to the four-parameter sigmoidal function, and the EC 50 values 
were calculated (Sigmaplot) (III). 
Each test was repeated three times with 3-6 parallel determinations in 
each. N was 6 in ATPase determinations, and 18 in the ATP test. The 
mean and SEM. of independent determinations at each concentration 
were calculated. In the statistical analysis ANOVA test was used. 
Statistical differences between treated samples and controls were 
evaluated by using one-way ANOVA with Dunnett’s post-test (GraphPad 
Prism) (IV).  
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RESULTS 
1. Effects of lead on rat synaptosomal membrane 
integral proteins  (I,II) 
The synaptosomes isolated from rat cerebrum were exposed to PbCl2 in 
five different concentrations (3, 6, 15, and 30 µM). The ATPase activities 
were determined after a one-hour exposure and AChE activities after a 
30 min exposure. Lead decreased the total ATPase activity, but had a 
slighter effect on Mg2+ -ATPase. A 50% inhibition of the total ATPase 
activity was found with 30µM lead concentration. No difference was found 
between the effects of the inorganic and organic metal salts studied. In in 
vitro experiments, inorganic lead decreased the synaptosomal ATPase 
activity dose-dependently. Statistically significant decreases were found 
at 9 µM concentration and at the higher concentrations, both in total 
ATPase and in Na+, K+ -ATPase activities. The activity of Mg2+ -ATPase 
decreased significantly only at the concentration of 30 µM. The 
approximate ED50 for total ATPase activity was 30 µM of lead in the 
incubation mixture.  In the AChE activity of synaptosomal membranes 
there was no marked decrease caused by lead at the same micromolar 
concentrations.  
In in vivo experiments the test diet (LACTAMIN R-469 containing 29 
mg PbCO3/kg) did not cause any difference in the development of the 
body weight of experimental and control rats  of both sexes. The lead 
concentration in whole blood (B-Pb) was significantly higher in the 
experimental group (0.35 µM/l)  than in the control group (0.20 µM/l). In in 
vivo experiments, inorganic lead in the diet during fetal and postnatal 
subchronic exposure caused a slight, but not statistically significant 
decrease in ATPase and AChE activities in cerebral synaptosomal 
membranes. 
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2. Combined effects of aluminium and ethanol on 
rat synaptosomal integral proteins  (III) 
In in vitro experiments the synaptosomes were exposed to different 
concentrations of test compounds. Al-lactate caused a decrease in total 
ATPase and in AChE activities concentration-dependently. The decrease 
in ATPase activity started at 0.2 mM concentration, and the EC50 was 1.1 
mM. The decrease in AChE activity started at 5-10mM concentration, and 
the EC50 value was 15.8 mM. The coexposure with EtOH (2mM) 
increased the EC50 values in both cases, but due to the great deviations 
in AChE values, the increase in the EC50 may be non-significant. The 
EC50 values of Al-lactate with 2mM EtOH exposure were 2.1 mM for 
ATPase and 19.6 mM for AChE. 
In in vivo experiments the 90-day exposure to aluminium and EtOH 
had no  effect on the development of the body weight of the rats. The 90-
day exposure to aluminium and EtOH had no  effect on the development 
of the body weight of the rats. The average body weight was 539g ( 
+12.1, SEM) in the male experimental rats and 546g (+16.6, SEM) in the 
male control rats. In the exposed females, average body weight was 
353g ( +7.8,SEM) and in the control females 350g ( +9.4, SEM). 
After the 90-day oral aluminium exposure (98,8 mg/kg/day), the serum 
aluminium concentration was 1.1 µM/l in the aluminium group and 1.3 
µmol/l in the Al-EtOH group. Both values differed significantly from the 
value 0.1 µM/l in the control group. EtOH ingestion had no effect on the 
blood aluminium level, but the coexposure with aluminium exposure 
decreased the whole blood EtOH content significantly (P<0.05). 
The 90-day aluminium exposure caused changes in the AChE and 
ATPase activities, measured two weeks after the last dosing. Immediately 
after the 90-day exposure there were no marked differences in the 
synaptosome integral enzyme activities between the exposed and the 
control rats. In comparison of the groups studied immediately after the 
exposure (group A) and two weeks after the exposure (group B), the 
normalized ATPase and AChE activities (% of corresponding control 
group value) were significantly lower in group B than in group A. 
Correspondingly, a significant decrease in the AChE activity was also 
found in  the aluminium with the EtOH –exposed rats of group B..  
3. Effects of aluminium and lead on the ATPase 
activity of mouse cerebral synaptosomes in vitro (IV)  
Aluminium exposure (at the concentrations 0.3 mM, 0.9 mM, 1.5 mM, 2.0 
mM, and 2.8 mM) caused decreases in synaptosomal ATPase and Mg2+-
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ATPase activities starting from 0.9mM concentration and continuing over 
the whole dose range of the tests. GDNF+/- synaptosomes were less 
sensitive to aluminium than WT mouse cerebral synaptosomes. This was 
seen in the slighter decrease in the activity of GDNF +/- Mg2+-ATPase 
compared to WT Mg2+-ATPase. The difference was statistically significant 
(P<0.05) at 1.5 mM, 2.0 mM and 2.8 mM dose levels of aluminium.  
In the isolated cerebral synaptosomal membranes, lead exposure (at 
the concentration 0.001 mM, 0.003 mM, 0.006 mM, 0.009 mM, 0.015 
mM, and 0.030 mM) caused a dose-dependent decrease in the ATPase 
activity, starting from the 0.003 mM concentration. After 0.010 mM 
concentration, no further decreases in the ATPase activities were found. 
The decrease in the total ATPase activity was more prominent than in the 
Mg2+-ATPase activity. There were no significant differences between 
GDNF+/- synaptosome ATPase and WT synaptosome ATPase at 0.001- 
0.015 mM concentrations. At low concentrations GDNF+/- synaptosomal 
Mg2+ -ATPase was more sensitive to aluminium than WT cerebral 
synaptosomes. 
. 
4. Effects of lead and aluminium on cultured neural 
cell ATPase activities (I) 
The cells isolated from the cultures of fetal rat brain neurons were 
exposed to five different metal concentrations (3 µM, 6 µM, 9 µM, 15 µM, 
30 µM) as AlCl3, AlLc3, PbCl2, and lead acetate (PbAc2). The enzyme 
activities were determined after a one-hour exposure. 15 µM of lead 
decreased the total ATPase activity to 50% of the control activity. Mg2+ -
ATPase activity was decreased to 50% by 30 µM of lead. Aluminium 
decreased only slightly both enzyme activities at 30 µM concentration. In 
neural cell cultures there was no difference between the effects of 
inorganic and organic metal salts. 
5. ATP content in SH-SY5Y neuroblastoma cells 
after the exposure to aluminium and lead (IV) 
Aluminium exposure caused a dose-dependent decrease in cellular ATP 
content in the acute 24h cell toxicity test at 0.3 mM-2.8 mM 
concentrations. These are the same concentrations which also caused a 
decrease in the ATPase activity of the synaptosomal membranes of 
GDNF +/-. 
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In the cell toxicity test 24h exposure of the SH-SY5Y cell line in a 
culture), the ATP content of neuroblastoma SH-SY5Y cells did not 
decrease at the lead concentrations (0.003 mM-0.05 mM) which caused 
a decrease in the synaptosomal ATPase activities. Clear cell toxicity in 
the ATP test was found at higher lead concentrations (0.25 mM, 0.5 mM 
and 1.0 mM).  
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DISCUSSION 
It is estimated that only a small fraction of the 70 000 chemicals currently 
in commerce has been adequately assessed for neurotoxicity, and thus 
there is a need to develop cost-effective screens to assess substances 
for  potential neurotoxicity (Ehrich and Veronesi 1999). 
Synaptosomes (pinched-off nerve endings) retain a number of 
functions of the presynaptic nerve terminals (Rodriguez de Lores 1992). 
Any alterations in the integrity of synaptic membranes may lead to 
significant changes in these functions. Previous studies have shown that 
neural membrane integral proteins are targets for many neurotoxic 
chemicals such as solvents (Tähti et al. 1999) and pyrethroid compounds 
(Kakko et al. 2003). The toxic effects of metals are well reported, but the 
subcellular mechanisms underlying the neurotoxicity are not clear. Metal 
cations at micromolar concentrations have been reported to damage the 
plasma membrane, the first cellular organelle with which they come in 
contact via circulation. After entering the CNS, the neurotoxic metals can 
affect the proteins of neural membranes. In the present set of 
experiments the effects of aluminium and lead exposures were studied 
on the neural membrane integral enzymes ATPase and AChE in vivo and 
in vitro. The other aim was to compare the in vivo vs. in vitro membrane 
effects of these two metals.  
1. The effects of lead and aluminium on neural cell 
membrane ATPase in vitro 
Lead can enter the nervous tissue cells, The highest concentration has 
been found within mitochondria. Lead is also known to interfere with the 
functions of enzymes in neural cells. The study of the activity of Na+, K+ -
ATPase and AChE has proved to be an effective method to measure the 
neurotoxicity of lead (Jehan and Motlag 1995, Nehru and Dua 1997, 
Antonio et al. 2003). The data of the present study shows that lead and 
aluminium at micromolar concentrations inhibit the ATPase activities in 
rat brain synaptosomes and in primary neural cells.  In the present study, 
30 µM of lead caused a 50 % inhibition (IC50) of the total ATPase activity 
in synaptosomes (I,II). The results indicate that, in synaptosomes, Na+, 
K+ -ATPase is responsible for the change in total ATPase activity after 
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lead treatments, since the Mg2+ -ATPase was only inhibited at greater 
dose levels (Table 1) This indicates that Na+, K+ -ATPase is 
physiologically important in the synaptic region. Aluminium had no effect 
on the total ATPase activity at the concentrations (3-30 µM) studied 
(Table 2). Aluminium has been found to have a high IC50 8.3 mM (Lai et 
al. 1980). Both metals had a slighter effect on synaptosomal Mg2+ -
ATPase activity than on total ATPase activity. In isolated cultured neural 
cells the enzyme inhibition was similar to that in synaptosomal 
membranes (Hyppönen et al. 1993). The decrease in the activity of 
Na+,K+ -ATPase was responsible for the decrease in the activity of total 
ATPase. Both total ATPase and Mg2+ -ATPase activities were markedly 
inhibited by lead, but only slightly by aluminium. 
 
Table 1. Summary of inhibition of neural membrane integral enzymes by 
lead 
Experiment Exposure AChE Total ATPase Mg2+ATPase Ref 
1)
 In vivo 
exposure of rats 
via diet 
PbCO3 2) 93% 
NS (n=9) 
93% 
NS (n=9) 
- II 
In vitro isolated 
rat synaptosomes 
PbCl2 
PbAc2 
- 
15-30 µM ** 
15-30 µM *** 
(n=15) 
15-30 µM *** I 
In vitro rat 
synaptosomes 
PbCl2 3-30 µM 
NS (n=12 ) 
9*-30 µM** 
(n=12) 
30 µM * II 
In vitro mouse 
GDNF 
synaptosomes 
PbCl2 - 15*-30 µM ** 
(N=6) 
- IV 
1)
 Exposure to Pb via maternal test diet (during the whole pregnancy and suckling) and 
after weaning for two months 
2)
 compared to control 
* p<0.05, **p<0.01, ***p<0.001 
NS non-significant 
2. The neurotoxic effects of lead studied with 
ATPase and AChE in vivo 
In vivo exposure of rats to lead showed that there was no accumulation of 
lead via experimental diet, even when the exposure occured during 
gestation. The amount of lead absorbed after oral administration can vary 
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significantly depending on animal species, age, composition of diet and 
both physical and chemical forms of the inorganic lead compound (Bondy 
1988). In this study the low lead levels (B-Pb: 0.35 µM, 7 µg/100 ml) in 
the blood samples of exposed rats did not cause any significant decrease 
in the ATPase and AChE activities in synaptosomes, even though a slight 
but not significant decrease was seen (Table 1). In in vivo experiments, 
much higher lead concentrations (B-Pb 17-23 µg / 100ml) have caused 
an increase in glial specific glutamine synthetase, postnatally (Cookman 
et al. 1988).  
As for the effects of lead on the developing brain in man, even very 
low exposures (blood lead concentrations < 10 µg) should be taken into 
account. This means that the daily dietary exposure of children should 
not be more than 60-150 µg (Carrington and Bolger 1992). In studies on 
the neurological and psychological functions carried out on low-level lead 
exposure it is very difficult to define any safe level. Even the range 5-25 
µg /100 ml blood, which has been  accepted as normal,  causes 
neurobehavioral disturbances in children under school age (Needleman 
and Landrigan 2004). Studies on the low-level exposures of animal 
models together with different in vitro models are important to detect the 
targets of lead in the CNS and the different modes of action of lead. 
3. The combined effects of aluminium and ethanol 
in vivo and in vitro 
The effects of aluminium and EtOH exposures on the rat neural 
membrane integral enzymes ATPase and AChE were studied both in 
vitro and in vivo (III). The in vitro exposure of the synaptosomes to Al-
lactate showed a dose-dependent decreasing effect on the activities of 
ATPase and AChE. The coexposure with 2mM EtOH increased the EC50  
(effective concentration) values of Al-lactate for both ATPase and AChE, 
indicating that EtOH may enhance the effects of aluminium on membrane 
functions (Table 2). In previous studies on the effects of EtOH on neural 
membranes, I have found an increase in the enzyme activities at 2mM 
concentrations.   
The total ATPase measured is a combination of the activities of Na+, 
K+ and Mg2+-ATPases. The clearly decreasing effect of in vitro aluminium 
exposure in this study can be explained by the interaction of aluminium 
with Mg2+, because ATPase has a tendency to form stronger complexes 
with Al3+ than with Mg2+ (Lai and Blass 1984). Furthermore the Al3+ -ATP 
complex acts as an inhibitor with respect to Mg2+-ATPase. Depending on 
the brain region and the cell type affected, there may be variations in the 
inhibition of ATPase. It has been documented that the Na+, K+-ATPase 
of astrocytes is more sensitive for aluminium that of neuronal 
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synaptosomes (Rao 1992). This difference may be dependent on the fact 
that in the brain there are different Na+, K+-ATPase isoforms with unique 
cellular and regional distributions (Urayama et al. 1989). 
 
Table 2. Summary of the effects of aluminium and EtOH on neural 
membrane integral enzymes  
Experiment Exposure AChE Total ATPase Mg2+ATPase Ref 
1)
 In vivo 
exposure of 
rats  
AlLc3 
Al + EtOH  
3) 110%** 
115%*** 
110%** 
NS  
- III 
2) AlLc3 
Al + EtOH 
NS 
NS 
NS 
NS 
- III 
In vitro rat 
synaptosomes 
AlCl3 
AlLc3 
- 
NS 
NS 
NS 
NS 
I 
 
In vitro rat 
synaptosomes 
AlLc3 5-10 mM 
(EC50 15.8 
mM) 
0.2 mM 
(EC50 1.1 mM) 
 
- III 
In vitro mouse 
GDNF 
synaptosomes 
AlLc3 - 0.9-30 mM ** 
(N=6) 
2-30 mM** IV 
1)
 immediately after the 90-day exposure to Al 
2)
 after 2-week recovery 
3)
 compared to control 
* p<0.05, **p<0.01, ***p<0.001 
NS non-significant 
 
There have been many individual studies on the in vitro and in vivo 
effects of aluminium, but there are few combination studies. Zatta et al. 
reported that aluminium is a strong activator of AChE. Increased AChE 
activity was found in brain homogenates prepared from mice treated for 
three months with AlCl3 or AlLc3. AChE was activated to a lesser extent in 
vitro (Zatta et al. 2002). In the present in vivo study, the concentration of 
serum aluminium in rat was 1.2 µM after 90-day exposure. Thus, the 
concentration of aluminium in the brain of the exposed rats obviously 
could be below 1.2 µM, as only a small fraction of aluminium is known to 
enter the CNS (Fatemi et al. 1991). But after the 90-day exposure, 
accumulation of aluminium will occur, and the concentration can be even 
higher than that measured in blood. In in vitro, the first indication of the 
decreasing effect of aluminium exposure on ATP activity was at the 
concentration of over 0,3 mM, and on AChE activity at over 1 mM 
concentration. Thus in the 90-day exposure the acutely effective dose 
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levels were not reached. EtOH did not affect the aluminium absorption 
significantly. The serum level was similar in the rats exposed to 
aluminium and in those exposed to aluminium with EtOH. However, 
aluminium decreased the EtOH level in the blood of the experimental rats 
which were exposed to both aluminium and EtOH. This can be explained 
by the fact that aluminium inhibits the absorption of EtOH in the digestive 
tract. Aluminium has been shown to be neurotoxic in experimental 
animals, although there is considerable variation among species 
(Anonymous 1997). In some long-term experiments the concentration of 
aluminium in the blood and liver of rats exposed both to aluminium and 
EtOH was higher than in those exposed to aluminium only (Flora et al. 
1991). In the present study, the highest values of blood aluminium were 
found in the rats coexposed to EtOH, but the differences were not 
statistically significant. It has also been considered that antacids based 
on aluminium salts may increase the risk of dementia in chronic heavy 
drinkers (Davis 1993). 
The 90-day exposure of rats to aluminium with EtOH caused changes 
in the synaptosomal integral enzymes, seen in the difference between the 
rats studied immediately and those studied two weeks after the exposure 
(III). The ATPase and AChE activities decreased during the two-week 
time after the last dosing. This could be caused by the aluminium dosing 
and explained by compensatory metabolic changes during the recovery 
time from the long-term aluminium exposure, but further studies are 
needed for a final explanation of the mechanism. Previously, behavioral 
impairments have been observed in rats exposed to soluble aluminium 
salts in the diet or drinking water at lower aluminium exposure (50 mg 
Al/kg/day) than that in my study. Lal et al. (1993) have found that the 
decrease in ATPase activities correlates with the impairments in the 
cognitive functions of rats exposed to aluminium. There is also evidence 
about the influence of age on aluminium-induced neurobehavioral effects 
and morphological changes in rat brain (Colomina et al. 2002). It seems 
that changes in ATPase activity can cause disturbances in the ion 
balance across the neural membrane. Bilkei-Gorzó (1993) found that the 
learning ability of rats in behavior tests was diminished by the 
subchronical oral treatment of aluminium salts. The effect was assumed 
to result from diminished cholinergic activity in the whole brain, based on 
the decrease in the activity of choline-acetyltransferase (CAT) (Bilkei-
Gorzó 1993). A dose-dependent decrease of synaptosomal high-affinity 
choline transport (HAChT) in the rat hippocampus has been found after 
intraventricular injection of AlCl3, but  the same concentration of 
aluminium citrate did not cause a similar effect (Zubenko and Hanin 
1989). Therefore, the toxic effect of aluminium appears to be dependent 
on the form in which it is administered.  
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4. The experimental models to study neurotoxic 
effects of aluminium and lead  
Although the (BBB) protects the CNS against environmental chemicals, 
lead and aluminium are known to pass the barrier (Zubenko and Hanin 
1989). However, only a small fraction of  the aluminium ingested is known 
to enter the CNS (II) (Kohila et al. 1995, Zheng et al. 2003). Because of 
their many active transport and receptor mechanisms, the neural 
membranes have been found to be vulnerable to neurotoxic substances. 
In general, metals are known to interfere with the functions of 
enzymes in neural cells. In this study with synaptosomes of rats and 
knockout GDNF+/- mice in vitro, lead exposure caused dose-dependent 
decrease of ATPase activity (I, II, IV). The neurological defects caused by 
lead have been found in in vivo animal studies on blood levels of 20 to 35 
mg / 100ml blood (Zheng et al. 2003). Blood lead levels as low as 10 µg 
/100ml have been associated with impaired neurobehavioral 
development in children (Markowitz 2000), and blood levels of 30 µg 
/100ml have been associated with elevated blood pressure and other 
adverse effects in adults. The safe levels are even lower, when the 
possibility of individual variations is taken into account. About 10% of 
ingested lead is absorbed in humans, while the corresponding figure for 
animals (rats) is 1%. The same plasma levels that cause neurological 
defects in humans do not result in clear behavioral disturbances in rats 
(Rostron 1982a, Petit et al. 1992). 
The data of aluminium toxicity derives from three major fields of 
investigation: human epidemiology studies, in vivo animal experiments, 
and in vitro experimentation. Aluminium has been reported in an ad hoc 
volume to be a potential and relevant cofactor in AD (Exley 1999). 
Aluminium can alter several biochemical mechanisms including the 
degeneration of the amyloid peptides, which suggests the way these 
potentially neurotoxic agents might interact in conditions such as AD. 
Depending on the brain region and the cell type affected, there may be 
variations in the inhibition of ATPases and in the impairment of the 
sodium pump (Hyppönen et al. 1993). The effects of aluminium on 
synaptosome ATPase were seen at concentrations which were also cell-
toxic and decreased the total ATP in the cells. The neurotoxic effects of 
aluminium in vivo are based on the accumulation of aluminium in specific 
brain areas, which can lead to neurofibrillary degeneration (Good and 
Perl 1993). Aluminium has been shown to be associated with 
neurofibrillary tangles and senile plaques of AD and dialysis 
encephalopathy. Studies on aluminium concentration in the brains of AD  
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patients have shown it to be as high as 12 µg/g (dry weight), whereas the 
control values obtained have not been greater than 2.7µg/g. The 
experimental animals (cats) treated with aluminium chloride gave even 
higher concentrations, although the control concentrations  were similar 
to those in patients with no AD (Crapper et al. 1973). More recent studies 
give some support to these findings, and analyses show small but 
significant increases of tissue aluminium concentrations in AD patients 
(Xu et al. 1992). 
The present study shows that in vitro metal exposures caused clear 
dose-dependent effects on neural membrane integral proteins in most 
cases. In in vivo exposures similar tendencies were observed, but the 
results were not clear, and often not statistically significant. In vivo many 
compensatory functions may cover these effects. In vitro experiments are 
especially important in showing the neurotoxic mechanisms. Based on 
the results of the present studies it can be concluded that in vitro and in 
vivo studies support each other, and the toxicological risk evaluations can 
be improved when both methods are included in the same experimental 
study schedule, as presented in Figure 4. 
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Figure 4. A scheme for the step-wise evaluation of the neurotoxicity of 
chemicals 
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Due to the complexity of the functions of the CNS, the evaluation of 
the neurotoxicity of chemicals is difficult. The in vitro studies can 
considerably improve the evaluation process officially based on animal 
experiments. The evaluation of a chemical with unknown neurotoxic 
potential can be started with the analysis of the physicochemical and 
structural properties of the chemical (in silico phase), followed  by studies 
on neural cell cultures. After this screening phase the animal experiments 
are necessary, because no relevant alternative tests are available for 
testing the neurotoxicity of a new compound. However, the in vitro 
screening can reduce the number of experimental animals needed in the 
in vivo phase. Especially the elucidation of the neurotoxic mechanisms in 
vitro is a valuable aid to give information on the whole process (Tähti et 
al. 1995, Tähti et al. 2003). 
If the risks of a chemical with previously known neurotoxic potential 
are to be evaluated, studies on its mechanisms will improve the risk 
evaluation as a whole. In the present study on the  mechanisms of lead 
and aluminium neurotoxicity, parallel in vitro and in vivo experiments 
showed changes in the activities of the brain synaptosome integral 
proteins. Generally, it is important to show that the mechanisms 
measured in vitro are also valid in vivo. This principle is important 
especially when in vitro tests for the detection of neurotoxicity are to be 
developed. 
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CONCLUSIONS 
In the present study, the effects of aluminium and lead exposures on the 
activities of the rodent neural membrane integral enzymes ATPase and 
AChE showed dose-dependent effects. The results indicate that the 
membrane proteins ATPase and AChE are one of the targets for the 
toxicity of aluminium and lead both in vivo and in vitro. 
 
1.  According to in vitro experiments, lead had a more prominent effect 
than aluminium on the integral protein activities. ATPase was a more 
sensitive target for lead than AChE. 
 
2  Subchronic (90-day) exposure of rats to aluminium in combination with 
exposure to EtOH caused a decrease in synaptosomal AChE activity. 
After two-week recovery, a significant decrease was also found in 
ATPase activity. According to this study, the synaptosomal integral 
proteins studied seemed to be targets for aluminium also in vivo. 
 
3.  GDNF seemed to have only minor importance in the synaptosomal 
membrane integral protein changes. Unlike in WT mouse synaptosomes, 
GDNF+/- synaptosomes showed significant changes in Mg2+ -ATPase in 
vitro. In the exposure to lead, both types of synaptosomes reacted 
similarly. The results indicate that GDNF plays a more important role in 
the exposure to aluminium than to lead in vitro. 
 
4.  The cell toxicity test based on the measurements of the total ATP 
content of neural cell line seemed to show the neurotoxic potential of 
aluminium, but not that of lead, as sensitively as the test based on the 
measurements of the integral proteins of isolated CNS synaptosomes. 
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